---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-002910"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:37:05.705172+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma reports $28.8M cash, focuses LNC on nucleic acids, pauses MAT2203 Phase 3 for BARDA

## Summary
- Preliminary cash of $28.8M at Dec 31, 2022, down from $49.6M at Dec 31, 2021; runway projected into Q2 2024.
- LNC platform achieves intracellular delivery of larger nucleic acids, mRNA stable >10 weeks at 4°C, low cytotoxicity.
- MAT2203 Phase 3 for cryptococcal meningitis paused pending BARDA evaluation; FDA meeting planned Q2 2023 for second Phase 3 study in four invasive fungal infections (approx. 100 patients).
- BioNTech collaboration: in vivo studies start Q1 2023, data expected Q2 2023; Resilience initial data in Q2/Q3 2023; Genentech extended through 2023.

## SEC filing metadata
- accession: 0001493152-23-002910
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223002910/0001493152-23-002910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223002910/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-002910
- JSON: https://secwatch.observer/filing/0001493152-23-002910.json
- Plain text: https://secwatch.observer/filing/0001493152-23-002910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.